These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 29589331)

  • 1. Population Pharmacokinetic Analysis of Asunaprevir in Subjects with Hepatitis C Virus Infection.
    Zhu L; Li H; Chan P; Eley T; Gandhi Y; Bifano M; Osawa M; Ueno T; Hughes E; AbuTarif M; Bertz R; Garimella T
    Infect Dis Ther; 2018 Jun; 7(2):261-275. PubMed ID: 29589331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population Pharmacokinetic Analysis for Daclatasvir and Asunaprevir in Japanese Subjects With Chronic Hepatitis C Virus Infection.
    Osawa M; Ueno T; Ishikawa H; Imai Y; Garimella T
    J Clin Pharmacol; 2018 Nov; 58(11):1468-1478. PubMed ID: 30063254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population Pharmacokinetic Analysis of Daclatasvir in Subjects with Chronic Hepatitis C Virus Infection.
    Chan P; Li H; Zhu L; Bifano M; Eley T; Osawa M; Ueno T; Hughes E; Bertz R; Garimella T; AbuTarif M
    Clin Pharmacokinet; 2017 Oct; 56(10):1173-1183. PubMed ID: 28066880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population Pharmacokinetic Analysis of Daclatasvir, Asunaprevir, and Beclabuvir Combination in HCV-Infected Subjects.
    Osawa M; Ueno T; Shiozaki T; Ishikawa H; Li H; Garimella T
    Clin Pharmacol Drug Dev; 2019 Aug; 8(6):802-817. PubMed ID: 30629858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of the NS3 Protease Inhibitor, Asunaprevir (ASV, BMS-650032), in Phase I Studies in Subjects With or Without Chronic Hepatitis C.
    Eley T; He B; Huang SP; Li W; Pasquinelli C; Rodrigues AD; Grasela DM; Bertz RJ
    Clin Pharmacol Drug Dev; 2013 Oct; 2(4):316-27. PubMed ID: 27121936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exposure-Response (Efficacy) Analysis of Daclatasvir and Asunaprevir in Japanese Patients With Hepatitis C Virus Infection.
    Ueno T; Osawa M; Imai Y; Ishikawa H; Garimella T
    J Clin Pharmacol; 2018 Nov; 58(11):1479-1488. PubMed ID: 30063245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study.
    Manns M; Pol S; Jacobson IM; Marcellin P; Gordon SC; Peng CY; Chang TT; Everson GT; Heo J; Gerken G; Yoffe B; Towner WJ; Bourliere M; Metivier S; Chu CJ; Sievert W; Bronowicki JP; Thabut D; Lee YJ; Kao JH; McPhee F; Kopit J; Mendez P; Linaberry M; Hughes E; Noviello S;
    Lancet; 2014 Nov; 384(9954):1597-605. PubMed ID: 25078304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders.
    Lok AS; Gardiner DF; Hézode C; Lawitz EJ; Bourlière M; Everson GT; Marcellin P; Rodriguez-Torres M; Pol S; Serfaty L; Eley T; Huang SP; Li J; Wind-Rotolo M; Yu F; McPhee F; Grasela DM; Pasquinelli C
    J Hepatol; 2014 Mar; 60(3):490-9. PubMed ID: 24444658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of daclatasvir and asunaprevir for hepatitis C virus genotype 1b infection.
    Nam HC; Lee HL; Yang H; Song MJ
    Clin Mol Hepatol; 2016 Jun; 22(2):259-66. PubMed ID: 27377910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical Pharmacokinetics and In Vitro Metabolism of Asunaprevir (BMS-650032), a Potent Hepatitis C Virus NS3 Protease Inhibitor.
    Mosure KW; Knipe JO; Browning M; Arora V; Shu YZ; Phillip T; Mcphee F; Scola P; Balakrishnan A; Soars MG; Santone K; Sinz M
    J Pharm Sci; 2015 Sep; 104(9):2813-23. PubMed ID: 25631585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Asunaprevir for hepatitis C: a safety evaluation.
    Gentile I; Zappulo E; Buonomo AR; Scotto R; Borgia G
    Expert Opin Drug Saf; 2015 Oct; 14(10):1631-46. PubMed ID: 26329454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrated pharmacokinetic/viral dynamic model for daclatasvir/asunaprevir in treatment of patients with genotype 1 chronic hepatitis C.
    Wang HC; Ren YP; Qiu Y; Zheng J; Li GL; Hu CP; Zhou TY; Lu W; Li L
    Acta Pharmacol Sin; 2018 Jan; 39(1):140-153. PubMed ID: 28880015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1-infected treatment-naive patients.
    Everson GT; Sims KD; Thuluvath PJ; Lawitz E; Hassanein T; Rodriguez-Torres M; Desta T; Hawkins T; Levin JM; Hinestrosa F; Rustgi V; Schwartz H; Younossi Z; Webster L; Gitlin N; Eley T; Huang SP; McPhee F; Grasela DM; Gardiner DF
    Liver Int; 2016 Feb; 36(2):189-97. PubMed ID: 26473667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of a fixed dose combination tablet of asunaprevir + beclabuvir + daclatasvir for the treatment of Hepatitis C.
    Zappulo E; Scotto R; Buonomo AR; Maraolo AE; Pinchera B; Gentile I
    Expert Opin Pharmacother; 2020 Feb; 21(3):261-273. PubMed ID: 31914336
    [No Abstract]   [Full Text] [Related]  

  • 15. Effective Treatment With Daclatasvir and Asunaprevir in Kidney Transplant Patients Infected With Hepatitis C Virus: A Report of Two Cases.
    Koshino K; Ushigome H; Masuda K; Matsuyama T; Harada S; Nakamura T; Nobori S; Iida T; Yoshimura N
    Transplant Proc; 2017 Jun; 49(5):1053-1055. PubMed ID: 28583525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimating the Long-Term Clinical and Economic Outcomes of Daclatasvir Plus Asunaprevir in Difficult-to-Treat Japanese Patients Chronically Infected with Hepatitis C Genotype 1b.
    McEwan P; Ward T; Webster S; Yuan Y; Kalsekar A; Broglio K; Kamae I; Quintana M; Berry SM; Kobayashi M; Inoue S; Tang A; Kumada H
    Value Health Reg Issues; 2014 May; 3():136-145. PubMed ID: 29702919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Asunaprevir: A Review of Preclinical and Clinical Pharmacokinetics and Drug-Drug Interactions.
    Eley T; Garimella T; Li W; Bertz RJ
    Clin Pharmacokinet; 2015 Dec; 54(12):1205-22. PubMed ID: 26177803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection.
    Everson GT; Sims KD; Rodriguez-Torres M; Hézode C; Lawitz E; Bourlière M; Loustaud-Ratti V; Rustgi V; Schwartz H; Tatum H; Marcellin P; Pol S; Thuluvath PJ; Eley T; Wang X; Huang SP; McPhee F; Wind-Rotolo M; Chung E; Pasquinelli C; Grasela DM; Gardiner DF
    Gastroenterology; 2014 Feb; 146(2):420-9. PubMed ID: 24184132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of treatment with daclatasvir and asunaprevir for recurrent hepatitis C after liver transplantation.
    Honda M; Sugawara Y; Watanabe T; Tateyama M; Tanaka M; Uchida K; Kawabata S; Yoshii D; Miura K; Isono K; Hayashida S; Ohya Y; Yamamoto H; Sasaki Y; Inomata Y
    Hepatol Res; 2017 Oct; 47(11):1147-1154. PubMed ID: 28002876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction of immunosuppressants with HCV antivirals daclatasvir and asunaprevir: combined effects with mycophenolic acid.
    de Ruiter PE; Gadjradj Y; de Knegt RJ; Metselaar HJ; Ijzermans JN; van der Laan LJ
    World J Transplant; 2018 Sep; 8(5):156-166. PubMed ID: 30211024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.